# Ipamorelin: Research Overview — Pure Amino Peptides > A cited literature summary of Ipamorelin: five-amino-acid GH-secretagogue, GHS-R1a selectivity, human PK data, failed Phase 2 RCT, WADA prohibition. Research peptide framing, no dosing. A synthetic pentapeptide engineered for protease resistance and GH-secretagogue selectivity — with real human PK data, a failed Phase 2 trial, and no approved indication. ## The short version Ipamorelin is a synthetic five-amino-acid peptide designed to selectively activate the ghrelin receptor (GHS-R1a) on pituitary cells, triggering a discrete pulse of growth hormone (GH) release. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2 — notation that rewards a closer look, because it is not a natural sequence: it uses two D-amino acids (mirror-image versions of the standard L-forms) and a synthetic first residue (alpha-aminoisobutyric acid, Aib) that normal digestive enzymes cannot cleave efficiently. That protease resistance is structural, not accidental. Ipamorelin's defining pharmacological feature is selectivity: at doses far above its GH-releasing threshold, it does not meaningfully raise ACTH, cortisol, or prolactin — a cleaner profile than older GH-releasing peptides. There is actual human pharmacokinetic data for it [9], which puts it ahead of BPC-157 on that dimension. But the only published Phase 2 controlled trial — investigating ipamorelin for postoperative gut recovery — missed its primary endpoint [8], and ipamorelin has never been approved as a drug by any regulatory authority. It has never been approved. The coverage here is chemistry and literature; it is not advice and it lists no doses. ## What it is **Ipamorelin** (research designation NNC 26-0161 / NNC-26-0161) is a synthetic pentapeptide (five amino acids) derived from the GHRP-1 scaffold by removal of the central Ala-Trp dipeptide, which both shortens the chain and changes receptor subtype selectivity. Its sequence is: **Aib-His-D-2-Nal-D-Phe-Lys-NH2** Each unusual residue serves a structural purpose: - *Aib (alpha-aminoisobutyric acid) at position 1* — a synthetic residue with two methyl groups in place of the alpha-hydrogen, creating bulkier local geometry that protects the peptide bond from proteolytic attack. - *D-2-Nal (D-2-naphthylalanine) at position 3 and D-Phe (D-phenylalanine) at position 4* — D-amino acids are mirror images of the standard L-forms found in proteins. Most peptidases (proteases that cut peptide chains) are stereospecific: they cut L-bonds efficiently but cannot grip D-bonds in the same way. These positions confer substantial resistance to enzymatic degradation. - *C-terminal NH2 (amide)* — the amide group at the chain's end protects it from carboxypeptidases. This is deliberate medicinal chemistry: the goal was a ghrelin receptor agonist that would survive long enough in biological fluids to reach its target intact. A selective agonist of the ghrelin / GH secretagogue receptor (GHS-R1a). ## How it works Ipamorelin selectively activates **GHS-R1a** (the ghrelin receptor) expressed on pituitary somatotroph cells. Binding triggers a pulse of growth hormone release by a mechanism distinct from (and complementary to) GHRH (growth hormone-releasing hormone). This complementarity is the rationale for the popular CJC-1295 + ipamorelin combination in research settings — two different routes to GH release, combined — though that combination protocol itself has not been studied in a controlled trial. **Selectivity vs. older GHRPs.** Earlier growth-hormone-releasing peptides (GHRP-6, GHRP-2) activate GHS-R1a but also raise ACTH and cortisol meaningfully, with GHRP-2 also raising prolactin. Ipamorelin does not produce these off-target hormone increases at doses far above its GH-releasing threshold in rats and swine. This selective profile is ipamorelin's defining pharmacological feature and is established in the founding characterization [9]. **Additional targets.** GHS-R1a is also expressed in enteric and vagal neurons involved in gut motility (which is why it was studied for postoperative ileus), in pancreatic islet cells where it has a GH-independent direct insulinotropic effect (shown ex vivo), and in hypothalamic appetite circuits where ghrelin-receptor agonism has a class-level orexigenic (appetite-stimulating) effect. **Human pharmacokinetics.** In healthy male volunteers given five 15-minute IV infusions at doses of 4.21–140.45 nmol/kg, ipamorelin showed dose-proportional kinetics: terminal half-life approximately 2 hours, clearance 0.078 L/h/kg, steady-state volume of distribution 0.22 L/kg. The GH response peaked approximately 40 minutes post-dose as a single discrete pulse [9]. ## What the research shows *Bone growth in rats.* Subcutaneous ipamorelin at 18, 90, and 450 µg/day (divided three times daily for 15 days) dose-dependently increased longitudinal bone-growth rate in adult female rats from 42 µm/day (vehicle) to 44, 50, and 52 µm/day respectively, with no change in systemic IGF-1 or IGF-binding proteins [10]. The absence of an IGF-1 change at modest doses is cited as evidence for a partly local or GH-pulse-driven skeletal effect distinct from chronic IGF-1 elevation. *Human pharmacokinetics — the best-characterized human dataset.* Population PK/PD modeling in healthy male volunteers established the kinetic parameters above and confirmed single-pulse GH release peaking ~40 minutes post-IV-dose [9]. This is one of the only human ipamorelin datasets and one of the better-characterized PK profiles for any research peptide. *Phase 2 RCT — postoperative ileus.* The only published Phase 2 randomized controlled trial (NCT00672074) enrolled 114 adults undergoing bowel resection and randomized them to ipamorelin 0.03 mg/kg IV twice daily for up to 7 days or placebo. The primary endpoint — median time to first tolerated meal — was 25.3 hours with ipamorelin vs. 32.6 hours with placebo, a difference that did not reach statistical significance (p = 0.15) [8]. Treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm vs. 94.8% of placebo. The primary endpoint was missed; the trial provides the most rigorous human safety snapshot but no proof of efficacy for this indication. *Class-level cardiovascular signal.* A 28-day safety study of a structurally distinct GHS-R1a agonist (not ipamorelin) in rats found dose-dependent myocardial degeneration and necrosis detectable by histopathology and elevated FABP3, though serum cardiac troponin was not elevated at the tested doses [7]. This is a class-level signal for chronic systemic GHS-R1a agonism — ipamorelin was not the tested compound and has no equivalent long-duration study. *Weight and appetite research.* In a ferret cisplatin-induced weight-loss model, intraperitoneal ipamorelin at 1–3 mg/kg inhibited body-weight loss by approximately 24% on the last day of the delayed phase (48–72 hours) but had no anti-emetic effect — a peripheral mechanism distinct from the central route seen with a related compound [6]. ## Reported effects, cautions and safety **Anecdotal, not clinical evidence.** People in research-use communities most consistently cite deeper, more restorative sleep — falling asleep faster, sleeping more heavily, waking more rested — as the primary reported benefit, often appearing within one to two weeks of a pre-bed protocol. Vivid or intense dreams in the first one to two weeks are frequently noted alongside this. Faster physical recovery between training sessions and reduced post-training soreness are the next most-cited benefits. A smaller group reports a gradual shift toward leaner body composition over weeks to months, described as subtle and slow. All of these are anecdotal, unverified, and not clinical findings. On the adverse side, facial flushing and head-rush shortly after injection — a warm flush across the face or upper chest lasting up to an hour — is very widely reported and is often treated in community threads as a sign the peptide is active. Tingling or numbness in hands and feet, mild water retention, and increased appetite in the hours after injection are occasionally reported, the last consistent with the ghrelin-receptor mechanism. Transient lightheadedness or a spacey feeling after injection, injection-site irritation, and a diminishing perceived response after three to four months of continuous use round out the most common adverse anecdotes. **Safety cautions from the literature:** - *Never approved, Phase 2 failed.* The only RCT missed its primary endpoint [8]. No Phase 3 trial has been conducted. "Never approved" reflects failed efficacy programs, not an incomplete development pipeline. - *Active malignancy or proliferative conditions.* GH stimulates IGF-1, a characterized mitogen. Chronically raising GH-pulse amplitude carries a theoretical concern about proliferative activity in pre-existing tumors. This is mechanism-based, not drawn from observed oncologic events in any ipamorelin study. - *Diabetes, impaired glucose tolerance.* GH reduces insulin sensitivity, and ipamorelin has a direct insulinotropic effect on pancreatic islets in preclinical data. The combined glycemic impact in people with existing insulin dysregulation is unpredictable from current data. - *Cardiovascular disease.* The class-level cardiotoxicity signal from the GHS-R1a agonist rat study [7] — and the GH-axis fluid-retention mechanism in states of GH excess — makes chronic systemic GHS-R1a agonism a concern for people with underlying cardiac vulnerability. - *Unknown long-term safety; unverified supply.* No long-term human safety database exists for ipamorelin. Research-grade material from unregulated suppliers is not subject to pharmaceutical quality assurance. - *WADA-prohibited.* Ipamorelin is banned at all times in sport under the WADA category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), with established urine detection methods. Competitive athletes face real sanctions risk. ## Where it fits in peptide chemistry Ipamorelin is the most deliberately engineered peptide on this desk. Its sequence is not derived from a natural protein — it is a medicinal chemistry product, designed amino acid by amino acid for selectivity, protease resistance, and a specific receptor profile. The D-amino acids and synthetic Aib residue are structure-function choices, not natural occurrences. Among the three peptides here, it is the only one with a real controlled human trial (which it failed), the only one with population PK/PD data from volunteers, and the only one with a known and well-characterized receptor target. It is also the only one with a class-level cardiovascular safety signal (albeit in a different compound), and the one with the most straightforward regulatory verdict: never approved, studied in humans for one indication, missed the endpoint. See [GHK-Cu](/ghk-cu) for the most human-documented compound on this desk, [BPC-157](/bpc-157) for the deepest animal record, or the [comparison page](/compare) for a structured side-by-side of all three. --- A literature digest built around the chemistry — sequence, structure, mechanism, evidence — not the marketing.